Page last updated: 2024-12-05

2-naphthol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Naphthol, also known as beta-naphthol, is an organic compound with the formula C10H7OH. It is a white solid that is slightly soluble in water. 2-naphthol is a key intermediate in the synthesis of many dyes, pharmaceuticals, and other organic compounds. It is also used as a disinfectant and antiseptic. 2-naphthol is synthesized by the sulfonation of naphthalene, followed by alkali fusion. It is a versatile starting material for various reactions, including electrophilic aromatic substitution, diazotization, and coupling reactions. 2-Naphthol is studied extensively due to its importance in industrial processes and its potential biological activity. It has been investigated for its antimicrobial, antioxidant, and anticancer properties. However, it is also known to be a skin irritant and may cause allergic reactions. Further research is needed to understand its safety and efficacy in various applications.'

2-naphthol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-naphthol : A naphthol carrying a hydroxy group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8663
CHEMBL ID14126
CHEBI ID10432
SCHEMBL ID28781
MeSH IDM0091469

Synonyms (140)

Synonym
.beta.-naphthyl alcohol
developer ams
.beta.-monoxynaphthalene
nsc-2044
c.i. 37500
isonaphthol
2-naftolo
2-naftol
nsc2044
developer bn
.beta.-hydroxynaphthalene
c.i. developer 5
.beta.-naftolo
azogen developer a
naphthol b
betanaphthol
2-naphtol
.beta.-naphthyl hydroxide
c.i. azoic coupling component 1
.beta.-napthol
wln: l66j cq
.beta.-naftol
developer sodium
.beta.-naphthol
2-hydroxynaphthalene
naphthol, beta
.beta.-naphtol
2-naphthalenol
developer a
AB-131/40299865
SGCUT00131
nsc 2044
einecs 205-182-7
beta-monoxynaphthalene
beta-naphthyl alcohol
ai3-00081
2-napththol
einecs 215-322-9
beta-naftol [dutch]
epa pesticide chemical code 010301
hsdb 6812
2-naftolo [italian]
beta-naftolo [italian]
beta-naphtol [german]
beta-naphthyl hydroxide
caswell no. 590
2-naphtol [french]
beta-napthol
brn 1817321
2-naftol [dutch]
beta-hydroxynaphthalene
CHEBI:10432 ,
naphthalen-2-ol
inchi=1/c10h8o/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-7,11
135-19-3
beta-naphthol
2-naphthol
TO_000010
2-naphthol, 98%
2-naphthol, 99%
AC-10464
naphthols
CHEMBL14126 ,
naphth-2-ol, 10
bdbm50159250
N0027
AKOS000119842
A806896
NCGC00249132-01
HMS3264N15
4-06-00-04208 (beilstein handbook reference)
dtxsid5027061 ,
dtxcid907061
tox21_303038
NCGC00257077-01
cas-135-19-3
NCGC00259433-01
tox21_201884
pharmakon1600-01504501
nsc-758883
nsc758883
03v ,
STL281866
beta-naftol
unii-p2z71cik5h
betanaphthol [nf]
beta-naphtol
ec 205-182-7
beta-naftolo
p2z71cik5h ,
FT-0613121
4B32
S6035
2-naphthol [inci]
betanaphthol [hsdb]
betanaphthol [ii]
2-naphthol [mi]
tolnaftate impurity a [ep impurity]
betanaphthol [mart.]
betanaphthol [who-dd]
CCG-213932
2-napthol
2-hydroxy naphthalene
napthalen-2-ol
naphth-2-ol
2-naphthylalcohol
SCHEMBL28781
antioxygene bn
naphthol, .beta.
sodium 2-naphthoxide (salt/mix)
microcidin (salt/mix)
AM86551
Q-200736
AB01314260_03
mfcd00004067
2-naphthol, fluorescence indicator, >=99.0%
2-naphthol, purum, >=98.0% (gc)
2-naphthol, bioxtra, >=99.0% (gc)
F0001-0455
sr-01000872753
SR-01000872753-1
2-naphthol, saj first grade, >=98.0%
D86186
2-naphthol, lr, >=98%
2-naphthol, 98.5%
naphthalen-2-ol (beta-naphthol)
SBI-0207084.P001
hydronaphthol
beta.-hydroxynaphthalene
HY-Y0110
Z57127515
CS-0008403
HR-0304
2-naphthol, purified
2-naphthol, reagent
Q949232
BRD-K21164796-001-01-0
EN300-18025
2-naphthol(flakes or chunks)
26716-78-9

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The short-term toxic effects of both sublethal and lethal concentrations of 1-naphthol were studied by light microscopy examination of the digestive gland-gonad complex of the common periwinkle Littorina littorea."( Short-term toxic effects of 1-naphthol on the digestive gland-gonad complex of the marine prosobranch Littorina littorea (L): a light microscopic study.
Angulo, E; Cajaraville, MP; Marigómez, JA,
)
0.13
" Zearalenone was about 3 times more toxic than its analogue zearalenol."( Toxicity of trichothecenes, moniliformin, zearalenone/ol, griseofulvin, patulin, PR toxin and rubratoxin B on protozoan tetrahymena pyriformis.
Cole, RJ; Cutler, HG; Nishie, K, 1989
)
0.28
"1-Naphthol was selectively toxic to human colorectal tumours compared to corresponding normal colonic tissue removed at surgery and maintained in short-term organ culture."( Selective toxicity of 1-naphthol to human colorectal tumour tissue.
Cohen, GM; d'Arcy Doherty, M; Wilson, GD, 1985
)
0.27
"The toxic effects of PR toxin were observed in mice, rats, anesthetized cats and isolated rat auricle preparations."( Acute toxicity of PR toxin, a mycotoxin from Penicillium roqueforti.
Chen, CF; Chen, FC; Wei, RD, 1982
)
0.26
" Benzoquinone was typically significantly more toxic than hydroquinone, while 1,2-naphthoquinone was typically significantly more toxic than 1,2-dihydroxynaphthalene."( Comparative toxicity of allelochemicals and their enzymatic oxidation products to maize fungal pathogens, emphasizing Fusarium graminearum.
Dowd, PF; Duvick, JP; Rood, T, 1997
)
0.3
" However, both the method of intracellular loading--which for many fluorophores involves endogenous esterase-mediated removal of hydrophobic groups such as acetoxymethyl esters (AM)--and fluorescence excitation of fluorophores in the cell, can produce toxic metabolites and reactive species."( Fluorophore toxicity in mouse eggs and zygotes.
Baltz, JM; Phillips, KP; Zhou, WL, 1998
)
0.3
" The potential for widespread human inhalation exposure to this toxic gas is recognized as a public health concern."( Changes in intracellular pH play a secondary role in hydrogen sulfide-induced nasal cytotoxicity.
Dorman, DC; Lancianese, S; Marshall, MW; McManus, BE; Roberts, ES; Wong, VA, 2006
)
0.33
" These results suggest that a gender-specific 1,4-naphthoquinone metabolic pathway may exist, which gives rise to unknown toxic metabolites."( In vitro toxicity of naphthalene, 1-naphthol, 2-naphthol and 1,4-naphthoquinone on human CFU-GM from female and male cord blood donors.
Croera, C; Ferrario, D; Gribaldo, L, 2008
)
0.6
" The compound was not toxic for Plectus cirratus (nematoda)."( Sesquiterpenes of the geosmin-producing cyanobacterium Calothrix PCC 7507 and their toxicity to invertebrates.
Becher, PG; Höckelmann, C; Jüttner, F; von Reuss, SH,
)
0.13
" The results obtained suggest that the Co(II) complex is much less toxic toward both cell lines and the decreased toxicity due to the complex was more pronounced with carcinoma A549 cells."( A complex of Co(II) with 2-hydroxyphenyl-azo-2'-naphthol (HPAN) is far less cytotoxic than the parent compound on A549-lung carcinoma and peripheral blood mononuclear cells: Reasons for reduction in cytotoxicity.
Chakrabarti, G; Choudhury, D; Das, S; Deb, T; Guin, PS; Saha, MB, 2011
)
0.37
" The oxidation of Sudan I increases its toxic effects and leads to covalent adducts in DNA."( Enzymes oxidizing the azo dye 1-phenylazo-2-naphthol (Sudan I) and their contribution to its genotoxicity and carcinogenicity.
Frei, E; Hodek, P; Martinek, V; Schmeiser, HH; Stiborova, M, 2014
)
0.67
" However, the direct toxic and anti-angiogenic effects of these pharmacologic agents have not been examined."( Toxicity and anti-angiogenicity evaluation of Pak1 inhibitor IPA-3 using zebrafish embryo model.
Ghouse, SS; Jagadeeshan, S; Malathi, R; Paneerselvan, N; Sagayaraj, RV, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" 2-Naphthyl sulphate was eliminated from haemolymph with a half-life < 10 h and was excreted in urine."( Pharmacokinetics of 2-naphthol following intrapericardial administration, and formation of 2-naphthyl-beta-D-glucoside and 2-naphthyl sulphate in the American lobster, Homarus americanus.
James, MO; Li, CL, 1997
)
0.62
" Thirty-seven novel substituted 6-phenyl-2-naphthols were synthesized and evaluated for 17beta-HSD1 inhibition, selectivity toward 17beta-HSD2 and the estrogen receptors (ERs) alpha and beta, and pharmacokinetic properties."( Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Bey, E; Bhoga, U; Frotscher, M; Hartmann, RW; Kruchten, P; Marchais-Oberwinkler, S; Messinger, J; Müller-Vieira, U; Neugebauer, A; Thole, H; Ziegler, E, 2008
)
0.93
" Plasma levels of TTI-101 were measured by LC-MS/MS, and pharmacokinetic results were analyzed with the PKSolver program."( Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease.
Chen, Z; Dong, Y; Eckols, TK; Kasembeli, MM; Mitch, WE; Tweardy, DJ; Wang, Y; Zhang, L, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
"A simple and highly selective molecularly imprinted solid-phase extraction (MISPE) combined with ultrasound-assisted dispersive liquid-liquid microextraction (DLLME) was developed for the determination of four Sudan dye (I, II, III, and IV) residues in sausage products."( Molecularly imprinted solid-phase extraction combined with ultrasound-assisted dispersive liquid-liquid microextraction for the determination of four Sudan dyes in sausage samples.
Qiao, J; Row, KH; Wang, H; Yan, H; Yang, G, 2011
)
0.37
" The objective of this research was to enhance the efficacy and drug-resistance for pancreatic carcinoma by using inhibition of SIRT1 combined with gemcitabine therapy methods."( Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
Gong, DJ; Guo, QQ; Yu, M; Zhang, JM; Zhuang, B, 2013
)
0.39
"A method for the simultaneous determination of Sudan I, II, III, and IV in blood samples by solid-phase extraction (SPE) combined with ultra-fast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) has been established."( [Simultaneous determination of four Sudan dyes in blood by solid-phase extraction combined with ultra-fast liquid chromatography-tandem mass spectrometry].
Chen, X; Fu, J; Hu, Y; Huang, K; Huang, X; Jin, M; Zhu, H; Zou, B, 2014
)
0.4
"For the effective removal of two typical odorants found in drinking water, 2-methylisoborneol (2-MIB) and geosmin (GSM), which cannot be effectively removed by the conventional water treatment processes, the advanced oxidation process of vacuum ultraviolet combined with chlorine (VUV/chlorine) was studied."( [Removing Typical Odorants in Drinking Water by Vacuum Ultraviolet Combined with Chlorine].
Chen, XH; Shi, LX; Sun, X; Tang, X; Zhang, Y, 2018
)
0.48
"A straightforward and efficient method was developed by ultrasound assisted emulsification microextraction (USAEME) combined with inductively coupled plasma optical emission spectroscopy (ICP/OES) to trace some toxic heavy metal ions in eight select farmed and four select imported rice samples."( Determination of toxic heavy metals in rice samples using ultrasound assisted emulsification microextraction combined with inductively coupled plasma optical emission spectroscopy.
Bozorgzadeh, E; Ebrahimi-Najafabadi, H; Pasdaran, A; Rezaei Bezenjani, R, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" After oral dosing, peak plasma concentrations of 1-naphthol occurred at 1 hr; parent compound made up less than 15% of the total radioactivity, and the bioavailability was 32%."( Disposition of 1-naphthol in the channel catfish (Ictalurus punctatus).
Plakas, SM; Stehly, GR,
)
0.13
"34 microL/min/cm, mean +/- SE, N = 4), calculated by dividing the absorption rate by the drug concentration, was significantly decreased (0."( Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs.
Awazu, S; Hayashi, M; Mizuma, T; Ohta, K, 1992
)
0.28
"To improve the bioavailability of the sparingly water-soluble drug, 1-(3,4-dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8- trimethoxynaphthalene (TA-7552), the usefulness of the co-grinding method with D-mannitol was investigated."( Enhancement of oral bioavailability and pharmacological effect of 1-(3,4-dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8- trimethoxynaphthalene (TA-7552), a new hypocholesterolemic agent, by micronization in co-ground mixture with D-mannitol.
Kubo, H; Mizobe, M; Osawa, T; Takashima, K, 1996
)
0.29
" Although the nature of the oil does have a deep effect on the phase behavior of the micellar systems, in the present investigation no differences in the yields and in the rates of product formation of the enzymatic system were observed on changing the oil, thus showing that in this case the substrate concentration or bioavailability is not the rate-limiting step."( Direct micellar systems as a tool to improve the efficiency of aromatic substrate conversion for fine chemicals production.
Baglioni, P; Berti, D; Bestetti, G; Briganti, F; Di Gennaro, P; Galli, E; Randazzo, D; Scozzafava, A, 2000
)
0.31
" The bioavailability of many organic contaminants is controlled in part by the nature, magnitude, and rate of sorption/desorption processes."( Biodegradation during contaminant transport in porous media: 6. Impact of sorption on coupled degradation-transport behavior.
Brusseau, ML; Famisan, GB, 2003
)
0.32
" The rate of absorption of alpha-NA in the presence of these polyphenols also varied."( Dietary polyphenols (-)-epicatechin and chrysin inhibit intestinal glucuronidation metabolism to increase drug absorption.
Awazu, S; Mizuma, T, 2004
)
0.32
"Presystemic intestinal metabolism reduces the intestinal absorption and bioavailability of orally administered drugs."( Factors affecting glucuronidation activity in Caco-2 cells.
Haga, M; Hayashi, M; Mizuma, T; Momota, R, 2004
)
0.32
" Potent and specific inhibitors of the CYP2A6 enzyme can be used in the future to increase nicotine bioavailability and thus make oral nicotine administration feasible in smoking cessation therapy."( Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Juvonen, RO; Poso, A; Rahnasto, M; Raunio, H; Wittekindt, C, 2005
)
0.33
" This in turn may affect the bioavailability of therapeutic drugs and toxicity levels of environmental chemicals, particularly procarcinogens."( Turmeric and curcumin modulate the conjugation of 1-naphthol in Caco-2 cells.
Naganuma, M; Okamura, S; Saruwatari, A; Tamura, H, 2006
)
0.33
" The combined biological action was optimized in micellar and microemulsion systems able to increase the bioavailability of the hydrophobic aromatic pollutants."( Combined action of a bacterial monooxygenase and a fungal laccase for the biodegradation of mono- and poly-aromatic hydrocarbons.
Branciamore, S; Briganti, F; Caño, MF; Duchi, I; Giardina, P; Gullotto, A; Randazzo, D; Sannia, G; Scozzafava, A; Tilli, S, 2008
)
0.35
" Our data also suggest that constituents of pomegranate juice, most probably punicalagin, impair the enteric functions of sulfoconjugation and that this might have effects upon the bioavailability of drugs and other compounds present in food and in the environment."( Pomegranate juice inhibits sulfoconjugation in Caco-2 human colon carcinoma cells.
Nakajima, Y; Narukawa, Y; Okamura, S; Saruwatari, A; Takeda, T; Tamura, H, 2008
)
0.35
" The degradation extent of 2-naphthol was further enhanced by nearly 10% after the addition of Tween 80, which increased the bioavailability of 2-naphthol."( Synergistic degradation of 2-naphthol by Fusarium proliferatum and Bacillus subtilis in wastewater.
Lian, B; Zang, S, 2009
)
0.95
"The present study describes the phenanthrene-degrading activity of Sphingomonas paucimobilis 20006FA and its ability to promote the bioavailability of phenanthrene."( Study of the degradation activity and the strategies to promote the bioavailability of phenanthrene by Sphingomonas paucimobilis strain 20006FA.
Berthe-Corti, L; Coppotelli, BM; Del Panno, MT; Dias, RL; Ibarrolaza, A; Morelli, IS, 2010
)
0.36
"Starting from a naphthol-based lead series with low oral bioavailability, we have identified potent TRPV1 antagonists with oral bioavailability in rats."( Tetrahydro-naphthols as orally available TRPV1 inhibitors.
Chan, F; Fujishima, H; Gupta, JB; Ikegami, Y; Madge, D; Marumo, M; Masuda, T; Mogi, M; Moriwaki, T; Tajimi, M; Urbahns, K; Yamamoto, N; Yasoshima, K; Yoshida, N; Yura, T, 2012
)
0.38
" Due to its poor bioavailability, reformulated versions of resveratrol with improved bioavailability have been developed (resVida, Longevinex(®) , SRT501)."( Sirtuin activators and inhibitors.
Alcaín, FJ; Villalba, JM,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" Other species of fish, including the more desirable salmonids with which the squawfish competes ecologically, are unaffected until this dosage has been increased severalfold."( A rapid and sensitive method for gas chromatographic analysis of the selective piscicide, "Squaxon".
Benson, WW; Gabica, J; Watson, M, 1976
)
0.26
"5 g/kg body weight) and 30-day repeat dosing (200, 100 and 50 mg/kg body weight) studies."( 1-Naphthol--single and repeated dose (30-day) oral toxicity studies in the mouse.
Buckley, P; Poole, A, 1989
)
0.28
" A significant increase in life span was observed in EATC but not in L1210 bearing mice dosed with 1-naphthol (50-60 mg/kg)."( Antitumour activity of 1-naphthol against L1210 leukaemia in vivo and Ehrlich ascites tumour cells in vivo and in vitro.
Cohen, GM; d'Arcy Doherty, M; Jones, M, 1986
)
0.27
" Appreciable quantities of 1- and 2-naphthol (7-20% of dose) and 1,2-dihydro-1-hydroxy-2-methylthionaphthalene (1-35% of dose) were in urine from rats dosed orally or intracecally with 1,2-dihydro-1-hydroxy-2-S-cysteinylnaphthalene and 1,2-dihydro-1-hydroxy-2-S-(N-acetyl)cysteinylnaphthalene."( Catabolism of premercapturic acid pathway metabolites of naphthalene to naphthols and methylthio-containing metabolites in rats.
Bakke, J; Gustafsson, B; Gustafsson, JA; Struble, C, 1985
)
0.55
"5 micrograms/kg per min) that was continued while dose-response curves to M-7 and cirazoline were generated."( Differential inhibition of vascular smooth muscle responses to alpha 1- and alpha 2-adrenoceptor agonists by diltiazem and verapamil.
Cavero, I; Langer, SZ; Lefèvre-Borg, F; Shepperson, N, 1983
)
0.27
" In a separate experiment the rats were also dosed with 150 mg/kg of unlabeled 5A1N daily for 4 consecutive days."( Characterization of the urinary metabolites of 5-amino-1-naphthol in the rat.
Divincenzo, GD; Enriquez, PM, 1984
)
0.27
" On the basis of dosimetric considerations and comparison with clinical treatment with tritiated methylnaphthoquinol diphosphate, practical dosage of 6-125I-iodo-MNDP is suggested and clinical indications and safety of use are discussed."( 6-125I-iodo-2-methyl-1,4-naphthoquinol bis (diammonium phosphate) as a potential radio-halogenated anti-cancer agent: in vitro investigations and possible clinical implications.
Brown, I; Carpenter, RN; Mitchell, JS, 1982
)
0.26
" Population values for the model parameters were obtained by a two-stage method allowing for repeated dosing per subject."( Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
Banken, L; Dingemanse, J; Guentert, TW; Holford, NH, 1994
)
0.29
" They were challenged with a maximum dosage of 80 mg of red cedar dust and spruce dust (control) with a rotahaler on separate days in a single blinded manner."( New method for an occupational dust challenge test.
Chan-Yeung, M; Chen, H; Lin, FJ, 1995
)
0.29
" Maximum plasma concentrations attained at 1 h after dosing ranged between 35."( The determination in human plasma of 1-hydroxy-2-naphthoic acid following administration of salmeterol xinafoate.
Carey, PF; Chilton, AS; Godward, RE, 1995
)
0.29
" Airway responsiveness was determined from the dose-response curve of Rrs to acetylcholine."( A 5-lipoxygenase inhibitor, FR110302, inhibits ozone-induced airway hyperresponsiveness in guinea pigs and dogs.
Asano, M; Hiroi, J; Imai, T; Inamura, N; Inoue, H; Masunaga, T; Nakahara, K; Notsu, Y; Takishima, T; Yatabe, T, 1993
)
0.29
" Analysis of the dose-response relationship of dioncophylline C revealed a 50% effective dosage (ED50) of 10."( Naphthylisoquinoline alkaloids against malaria: evaluation of the curative potentials of dioncophylline C and dioncopeltine A against Plasmodium berghei in vivo.
Assi, LA; Bringmann, G; Eling, W; François, G; Holenz, J; Timperman, G, 1997
)
0.3
" alpha1-Antagonistic effects of Z1046 were demonstrated by performing cumulative dose-response curves with the selective alpha1-agonist phenylephrine in the presence of Z1046."( Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries.
Buikema, H; de Zeeuw, D; Teisman, AC; van Gilst, WH; van Veldhuisen, DJ, 2000
)
0.31
" Daily dosing with A-77636 rapidly produced complete tolerance, as previously observed, whereas coadministration of the D2 agonist quinpirole plus A-77636 failed to either delay or prevent tolerance."( Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
Gulwadi, AG; Korpinen, CD; Mailman, RB; Nichols, DE; Sit, SY; Taber, MT, 2001
)
0.31
" IBAT inhibitors, a new class of hypocholesterolemic drugs may be used alone or in combination with HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia with low dosage and high compliance."( [Hypolipidemic drugs--ileal Na+/bile acid cotransporter inhibitors (S-8921 etc)].
Ichihashi, T, 2002
)
0.31
" A carbon dosage study done in a model system showed the amount of geosmin adsorbed to be greater for Filtrasorb 400 and the bagasse-based carbon at low carbon concentrations than for the pecan shell carbons, but geosmin adsorption was similar in all carbons at higher carbon dosages."( Physical and chemical properties of selected agricultural byproduct-based activated carbons and their ability to adsorb geosmin.
Losso, JN; Marshall, WE; Ng, C; Rao, RM, 2002
)
0.31
" For any given PAC dosage in a jar-test, removal efficiencies of 2-MIB and geosmin were increased in proportion to PAC dosage and were independent of their initial concentration in raw water for the tested PAC dosages."( Treatment of taste and odor material by oxidation and adsorption.
Baek, KH; Jung, SW; Yu, MJ, 2004
)
0.32
" A supralinear dose-response relationship was observed between urinary naphthols and naphthalene exposure."( Dose-dependent production of urinary naphthols among workers exposed to jet fuel (JP-8).
Egeghy, PP; Gibson, R; Rappaport, SM; Serdar, B, 2004
)
0.32
" The proposed method was successfully applied to the analysis of the investigated drugs in pure and pharmaceutical dosage forms with good accuracy and precision; the percentages of label claim ranged from 97."( Generic nonextractive spectrophotometric method for determination of 4-quinolone antibiotics by formation of ion-pair complexes with beta-naphthol.
Askal, HF; Darwish, IA; Marzouq, MA; Refaat, IH,
)
0.13
" Using PABPN1 nematodes that show muscle cell degeneration and abnormal motility, we found that increased dosage of the sirtuin and deacetylase sir-2."( Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1.
Abu-Baker, A; Brais, B; Catoire, H; Holbert, S; Néri, C; Parker, JA; Pasco, MY; Rouleau, GA; Tourette, C, 2008
)
0.35
" Compared with conventional anaerobic biological methods, the required dosage of organic cosubstrate was significantly reduced in the BES."( Decolorization of azo dyes in bioelectrochemical systems.
Keller, J; Mu, Y; Rabaey, K; Rozendal, RA; Yuan, Z, 2009
)
0.35
" Sudan-1 induced a non-linear dose-response curve for gene mutation and chromosomal damage in AHH-1 cells."( Metabolic influences for mutation induction curves after exposure to Sudan-1 and para red.
Johnson, GE; Parry, EM; Parry, JM; Quick, EL, 2010
)
0.36
"A series of novel hyper-cross-linked resins were synthesized from macroporous cross-linked chloromethylated poly(styrene-co-divinylbenzene) by adding different dosage of hydroquinone in Friedel-Crafts reaction."( Adsorption behaviors of a novel carbonyl and hydroxyl groups modified hyper-cross-linked poly(styrene-co-divinylbenzene) resin for beta-naphthol from aqueous solution.
Deng, L; He, C; Huang, J; Huang, K; Liu, J; Yan, C, 2010
)
0.36
" The results of the model applications showed that in particular the simplified equivalent background compound model is a useful tool to determine the PAC dosage required to reduce the T&O compounds below the threshold concentration."( Adsorption of geosmin and 2-methylisoborneol onto powdered activated carbon at non-equilibrium conditions: influence of NOM and process modelling.
Börnick, H; Engel, C; Worch, E; Zoschke, K, 2011
)
0.37
" These samples were collected just before each dosage of bepridil."( An LC method for quantifying bepridil in human plasma using 1-naphthol as the internal standard.
Goto, Y; Itoh, K; Iwai, S; Katoh, N; Kobayashi, M; Kuronuma, H; Narayama, Y; Noda, K; Tadano, K, 2011
)
0.37
" Hemolytic anemia was also found in G6PD-deficient mice at this dosage of naphthalene."( Development of a novel mouse model of severe glucose-6-phosphate dehydrogenase (G6PD)-deficiency for in vitro and in vivo assessment of hemolytic toxicity to red blood cells.
Fok, TF; Fung, KP; Gu, GJ; James, AE; Ko, CH; Li, CL; Li, K; Ng, PC; Wong, RP, 2011
)
0.37
" The assays were carried out using a 2(2) experimental designs whose variables were concentration of Mn(2+) (33 and 1,000 μM) and semicontinuous dosage of the H(2)O(2) (0."( Detoxification of azo dyes mediated by cell-free supernatant culture with manganese-dependent peroxidase activity: effect of Mn2+ concentration and H2O2 dose.
Contreras, E; Palma, C; Urra, J; Vásquez, C,
)
0.13
" Here the hypothesis is tested that the level of WEE1 has a dosage effect on growth and development in Arabidospis thaliana."( Gene dosage effect of WEE1 on growth and morphogenesis from arabidopsis hypocotyl explants.
Albani, D; Bitonti, MB; Doonan, JH; Francis, D; Herbert, RJ; Lentz Grønlund, A; Marchbank, AM; Nieuwland, J; Perrotta, L; Rogers, HJ; Siciliano, I; Spadafora, N, 2012
)
0.38
"There is a gene dosage effect of WEE1 on morphogenesis from hypocotyls both in vitro and in vivo."( Gene dosage effect of WEE1 on growth and morphogenesis from arabidopsis hypocotyl explants.
Albani, D; Bitonti, MB; Doonan, JH; Francis, D; Herbert, RJ; Lentz Grønlund, A; Marchbank, AM; Nieuwland, J; Perrotta, L; Rogers, HJ; Siciliano, I; Spadafora, N, 2012
)
0.38
"A dose-response relationship was observed between resveratrol and RGC survival."( The neuroprotective effect of resveratrol on retinal ganglion cells after optic nerve transection.
Kim, SH; Kim, YJ; Park, JH; Park, KH, 2013
)
0.39
"Co-removal of oscillatoria algae and its potential odorous metabolite dimethyl trisulfide (DMTS) in simulated algae-laden alkaline source water by potassium ferrate (K2FeO4) was investigated in contrast to potassium permanganate (KMnO4) pre-oxidation followed by polyferric chloride (PFC) under varying conditions, including pH, initial oxidant dosage and turbidity."( [Simultaneous removal of algae and its odorous metabolite dimethyl trisulfide in water by potassium ferrate].
Hu, SF; Li, QS; Ma, XY; Wang, HY; Zhang, ZH, 2013
)
0.39
" Choosing an appropriate H2O2 dosage (5 v%) (equivalent to 70."( Preparation of sewage sludge based activated carbon by using Fenton's reagent and their use in 2-naphthol adsorption.
Gu, L; Huang, S; Lou, Z; Wang, M; Wang, Y; Yuan, H; Zhang, D; Zhu, N, 2013
)
0.61
"Our results suggest that the developed formulation has a potential to replace the current daily dosing regimen to a less frequent dosing schedule."( Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study.
Arya, A; Banala, VT; Mishra, PR; Mishra, S; Mitra, K; Mittapelly, N; Pandey, G; Sharma, S; Shukla, S; Thalla, M, 2017
)
0.46
" Two oxidant dosage strategies were compared in terms of the organic removal performance: a simultaneous dosing strategy (SiDS) and a successive dosing strategy (SuDS)."( Microcystis aeruginosa-laden water treatment using enhanced coagulation by persulfate/Fe(II), ozone and permanganate: Comparison of the simultaneous and successive oxidant dosing strategy.
Chen, W; Cheng, X; Li, G; Liang, H; Liu, B; Qu, F; Van der Bruggen, B; Wang, T; Yu, H, 2017
)
0.46
" Specifically, intratracheal administration of low dosage of IPA-3 consistently decreases not only the airway inflammation but also the DC trafficking from lung to the MLNs."( Inhibition of p21-activated kinase 1 attenuates the cardinal features of asthma through suppressing the lymph node homing of dendritic cells.
Lu, M; Tang, L; Wang, X; Wu, J; Wu, X; Xu, C; Zhang, Q, 2018
)
0.48
" Hence, sludge should be treated within 4 d and excess PAFC dosing should be avoided."( Worse than cell lysis: The resilience of Oscillatoria sp. during sludge storage in drinking water treatment.
Jin, Y; Li, H; Ma, C; Pei, H; Sun, J; Xu, H, 2018
)
0.48
" Multiple linear regression analysis was used to analyze the relationship between the concentrations of 2-OH NAP and birth outcomes, and restricted cubic spline models were further used to examine the shapes of the dose-response association."( Maternal urinary 2-hydroxynaphthalene and birth outcomes in Taiyuan, China.
Cheng, L; Deng, Y; Duan, L; Li, J; Li, Y; Nie, J; Niu, Q; Perera, F; Tang, D; Yan, Z, 2018
)
0.48
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antinematodal drugA substance used in the treatment or control of nematode infestations.
genotoxinA role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
naphtholA member of the class of naphthols carrying a single hydroxy substituent at C-1 or C-2. A closed class.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Phenolic Malonylglucosides Biosynthesis213
phenolic malonylglucosides biosynthesis210
alkylnitronates degradation350

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency79.03610.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.97380.006038.004119,952.5996AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency7.98730.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency38.11120.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency49.61250.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency48.21070.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency44.03590.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency44.81180.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.41410.000817.505159.3239AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency48.50090.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency53.39590.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743077; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency5.49480.001024.504861.6448AID743215
aryl hydrocarbon receptorHomo sapiens (human)Potency37.71310.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency70.26710.001723.839378.1014AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency36.46980.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency77.95000.039147.5451146.8240AID1224845; AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency9.68850.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.54230.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency55.81510.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency2.49320.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency55.81510.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)17.00000.00011.774010.0000AID241334
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)139.97950.00443.889510.0000AID241172; AID420671
Cytochrome P450 2A5Mus musculus (house mouse)IC50 (µMol)77.99151.00004.20259.7051AID241174; AID420670
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sulfotransferase 1A1 Rattus norvegicus (Norway rat)Km8.00005.00007.571410.0000AID39219
Sulfotransferase 1E1Homo sapiens (human)Km77.95501.60004.63676.4000AID1639871; AID1639874
Sulfotransferase 1A1Homo sapiens (human)Km0.17000.17001.83436.6200AID1639868
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (162)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
sulfationSulfotransferase 1E1Homo sapiens (human)
ethanol catabolic processSulfotransferase 1E1Homo sapiens (human)
estrogen catabolic processSulfotransferase 1E1Homo sapiens (human)
steroid metabolic processSulfotransferase 1E1Homo sapiens (human)
estrogen metabolic processSulfotransferase 1E1Homo sapiens (human)
positive regulation of fat cell differentiationSulfotransferase 1E1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate metabolic processSulfotransferase 1E1Homo sapiens (human)
sulfationSulfotransferase 1E1Homo sapiens (human)
sulfationSulfotransferase 1A1Homo sapiens (human)
ethanol catabolic processSulfotransferase 1A1Homo sapiens (human)
catecholamine metabolic processSulfotransferase 1A1Homo sapiens (human)
xenobiotic metabolic processSulfotransferase 1A1Homo sapiens (human)
estrogen metabolic processSulfotransferase 1A1Homo sapiens (human)
amine metabolic processSulfotransferase 1A1Homo sapiens (human)
flavonoid metabolic processSulfotransferase 1A1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate metabolic processSulfotransferase 1A1Homo sapiens (human)
sulfationSulfotransferase 1A1Homo sapiens (human)
sulfationSulfotransferase 2A1Homo sapiens (human)
ethanol catabolic processSulfotransferase 2A1Homo sapiens (human)
xenobiotic metabolic processSulfotransferase 2A1Homo sapiens (human)
steroid metabolic processSulfotransferase 2A1Homo sapiens (human)
cholesterol metabolic processSulfotransferase 2A1Homo sapiens (human)
lipid catabolic processSulfotransferase 2A1Homo sapiens (human)
bile acid catabolic processSulfotransferase 2A1Homo sapiens (human)
thyroid hormone metabolic processSulfotransferase 2A1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate metabolic processSulfotransferase 2A1Homo sapiens (human)
sulfationSulfotransferase 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (57)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
estrone sulfotransferase activitySulfotransferase 1E1Homo sapiens (human)
steroid bindingSulfotransferase 1E1Homo sapiens (human)
protein bindingSulfotransferase 1E1Homo sapiens (human)
sulfotransferase activitySulfotransferase 1E1Homo sapiens (human)
flavonol 3-sulfotransferase activitySulfotransferase 1E1Homo sapiens (human)
steroid sulfotransferase activitySulfotransferase 1E1Homo sapiens (human)
aryl sulfotransferase activitySulfotransferase 1E1Homo sapiens (human)
aryl sulfotransferase activitySulfotransferase 1A1Homo sapiens (human)
protein bindingSulfotransferase 1A1Homo sapiens (human)
sulfotransferase activitySulfotransferase 1A1Homo sapiens (human)
flavonol 3-sulfotransferase activitySulfotransferase 1A1Homo sapiens (human)
steroid sulfotransferase activitySulfotransferase 1A1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate bindingSulfotransferase 1A1Homo sapiens (human)
alcohol sulfotransferase activitySulfotransferase 2A1Homo sapiens (human)
protein bindingSulfotransferase 2A1Homo sapiens (human)
sulfotransferase activitySulfotransferase 2A1Homo sapiens (human)
bile-salt sulfotransferase activitySulfotransferase 2A1Homo sapiens (human)
steroid sulfotransferase activitySulfotransferase 2A1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate bindingSulfotransferase 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytosolSulfotransferase 1E1Homo sapiens (human)
nuclear membraneSulfotransferase 1E1Homo sapiens (human)
cytoplasmSulfotransferase 1E1Homo sapiens (human)
cytosolSulfotransferase 1A1Homo sapiens (human)
cytoplasmSulfotransferase 1A1Homo sapiens (human)
cytosolSulfotransferase 2A1Homo sapiens (human)
cytoplasmSulfotransferase 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID420671Inhibition of human CYP2A62009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
AID266770Membrane permeability, CA(t)/CD(0) in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID636078Cytotoxicity against CHO cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID266760Permeability coefficient in silicon membrane using diffusion cells2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID168703Inhibition of Rana pipiens muscle activity.1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID636075Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 after 48 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID1127995Toxicity in Staphylococcus aureus ATCC 25923 after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID39219Apparent Michaelis constant (Km) against Arylsulfotransferase (AST IV)2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1125765Partition coefficient, log P of the compound in methanol-water mixture at 0.25 mg/ml by HPLC analysis2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Polyfluorinated bis-styrylbenzenes as amyloid-β plaque binding ligands.
AID39220Maximal velocity (Vmax) against Arylsulfotransferase (AST IV)2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID266763Membrane retention in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID241174Inhibitory concentration against mouse cytochrome P450 2A52005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1127996Toxicity in fluoroquinolone-resistant Staphylococcus aureus 1199B expressing NorA after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1127992Inhibition of NorA in fluoroquinolone-resistant Staphylococcus aureus 1199B assessed as potentiation of 4 ug/ml of ciprofloxacin MIC at 100 ug/ml after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID229377Ratio of kcat/Km determined for catalytic efficiency in sulfonation against AST IV2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID266762Effective permeability coefficient in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1574519Cytotoxicity against human MCF7 cells assessed as decrease in cell viability treated every 24 hrs measured after 72 hrs by alamar blue assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID266764Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID420670Inhibition of mouse CYP2A52009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID266765Effective permeability coefficient in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID266761Effective permeability coefficient in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID266768Membrane permeability, CA(t)/CD(0) in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1390975Inhibition of Mycobacterium tuberculosis IMPDH deltaCBS mutant assessed as reduction in NADH production at 1 mM using IMP as substrate preincubated for 5 mins followed by substrate addition measured for 32 mins in presence of NAD+2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID266766Dissociation constant, pKa of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID266769Membrane retention in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID310932Permeability across human Skin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID242975Ratio of IC50 for human CYP2A6 to that of mouse CYP2A5 was determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID266771Permeability in human skin2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1386829Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 72 hrs by cell-QB reagent based assay2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.
AID266767Membrane retention in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID241334Inhibitory concentration against recombinant human cytochrome P450 1A22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID636076Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID241172Inhibitory concentration against human cytochrome P450 2A62005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID644414Lipophilicity, log D of the compound in octanol-water at pH 7.4 by reverse-phase HPLC analysis2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).
AID1799876Thermal Denaturation Assay from Article 10.1002/cbic.201200521: \\Using a fragment-based approach to target protein-protein interactions.\\2013Chembiochem : a European journal of chemical biology, Feb-11, Volume: 14, Issue:3
Using a fragment-based approach to target protein-protein interactions.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2013Chembiochem : a European journal of chemical biology, Feb-11, Volume: 14, Issue:3
Using a fragment-based approach to target protein-protein interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,969)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990980 (24.69)18.7374
1990's471 (11.87)18.2507
2000's929 (23.41)29.6817
2010's1319 (33.23)24.3611
2020's270 (6.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.76 (24.57)
Research Supply Index8.33 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index97.32 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (0.39%)5.53%
Reviews93 (2.26%)6.00%
Case Studies29 (0.70%)4.05%
Observational1 (0.02%)0.25%
Other3,981 (96.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]